Extended Prophylaxis Comparing low molecular weight heparin (LMWH) to Aspirin in Total hip arthroplasty.

Trial Profile

Extended Prophylaxis Comparing low molecular weight heparin (LMWH) to Aspirin in Total hip arthroplasty.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Aspirin (Primary) ; Dalteparin sodium (Primary) ; Enoxaparin sodium
  • Indications Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EPCAT
  • Most Recent Events

    • 28 Jul 2011 This study was halted prematurely upon advice from the DSMB that the primary study objective for non-inferiority had been met
    • 28 Jul 2011 Results presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
    • 28 Jul 2011 Primary endpoint 'Thromboembolism-event-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top